

Elpro International Ltd.

17th Floor, Nirmal, Nariman Point
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

October 28, 2024

To,
BSE Limited
Phiroze Jeejeebhoy
Towers Dalal Street
Mumbai - 400 001

Dear Sir / Ma'am,

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Elpro International Limited (“the Company”) has acquired Equity Shares of “Laurus Labs Limited”.


The disclosure pursuant to Regulation 30 of the SEBI Listing Regulations read with Part A of Schedule III of the SEBI Listing Regulations, is attached as “**Annexure A**”.

This is for your information and record.

Thanking you,

For **Elpro International Limited**

**Mohit
Premchand
Dubey**

 Digitally signed by Mohit
Premchand Dubey
Date: 2024.10.28
17:16:55 +05'30'

**Mohit Premchand Dubey
Company Secretary and Compliance Officer
ICSI Membership Number :- ACS67363**

Encl. as above

Elpro International Ltd.

17th Floor, Nirmal, Nariman Point
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

Annexure A

Sr. No.	Particulars	Details								
1.	Name of the target entity, details in brief such as size, turnover etc.:	<p>Name of the target entity: Laurus Labs Limited</p> <p>Standalone Turnover as per last audited financials (FY 2023-24):</p> <table border="1"><thead><tr><th>Particulars</th><th>Amount (Rs. in crores)</th></tr></thead><tbody><tr><td>Revenue from Operations</td><td>4,812.39</td></tr><tr><td>Other Income</td><td>27.05</td></tr><tr><td>Total</td><td>4,839.44</td></tr></tbody></table>	Particulars	Amount (Rs. in crores)	Revenue from Operations	4,812.39	Other Income	27.05	Total	4,839.44
Particulars	Amount (Rs. in crores)									
Revenue from Operations	4,812.39									
Other Income	27.05									
Total	4,839.44									
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length":	No								
3.	Industry to which the entity being acquired belongs:	Pharmaceuticals								
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	Investment Purpose								
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	N.A.								
6.	Indicative time period for completion of the acquisition:	N.A.								
7.	Nature of consideration - whether cash consideration or share swap and details of the same:	Cash consideration								
8.	Cost of acquisition or the price at which the shares are acquired:	INR 10.00 Crores								
9.	Percentage of shareholding / control acquired and/or number of shares acquired:	Fresh Acquisition: 2,02,040 Equity Shares (Previous Holding: NIL)								

Elpro International Ltd.

17th Floor, Nirmal, Nariman Point
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	<p>Brief Background:</p> <p>As a research-driven pharmaceutical manufacturing organization, Laurus Labs has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients.</p> <p>Since its inception in 2005, Laurus Labs has been a leading developer and manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates. Laurus Labs rapidly expanded its pharmaceutical value chain to secure a global leadership position, especially in APIs across therapeutic areas including anti-retroviral (ARV), oncology, cardiovascular, and gastroenterology. This strong market position is further reinforced by their backward integration capabilities, enabling consistent quality and highly compliant operations across all regulatory standards.</p> <p>Line of Business: Pharmaceuticals</p> <p>Website of the Entity: www.lauruslabs.com</p> <p>Date of Incorporation: September 19, 2005</p> <p>Net Worth as on March 31, 2024 (Rs. in Crore): Rs. 4,207.05</p> <p>Profit After Tax as on March 31, 2024 (Rs. in Crore): Rs. 223.70</p> <p>Standalone Turnover of last 3 Financial Years:</p> <table border="1" data-bbox="759 1671 1506 1946"><thead><tr><th rowspan="2">Particulars</th><th colspan="3">Amount (Rs. In Crores)</th></tr><tr><th>FY 2023-24</th><th>FY 2022-23</th><th>FY 2021-22</th></tr></thead><tbody><tr><td>Revenue from Operations</td><td>4,812.39</td><td>5,773.45</td><td>4,707.04</td></tr><tr><td>Other Income</td><td>27.05</td><td>4.75</td><td>13.48</td></tr><tr><td>Total</td><td>4,839.44</td><td>5,778.20</td><td>4,720.52</td></tr></tbody></table>	Particulars	Amount (Rs. In Crores)			FY 2023-24	FY 2022-23	FY 2021-22	Revenue from Operations	4,812.39	5,773.45	4,707.04	Other Income	27.05	4.75	13.48	Total	4,839.44	5,778.20	4,720.52
Particulars	Amount (Rs. In Crores)																				
	FY 2023-24	FY 2022-23	FY 2021-22																		
Revenue from Operations	4,812.39	5,773.45	4,707.04																		
Other Income	27.05	4.75	13.48																		
Total	4,839.44	5,778.20	4,720.52																		

Elpro International Ltd.

17th Floor, Nirmal, Nariman Point
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

		Country in which the target has presence: India, Germany, UK
--	--	--